By Mill Chart
Last update: Oct 13, 2023
Our stock screener has spotted EXELIXIS INC (NASDAQ:EXEL) as a growth stock which is not overvalued. NASDAQ:EXEL is scoring great on several growth aspects while it also shows decent health and profitability. At the same time it remains remains attractively priced. We'll dive into each aspect below.
ChartMill assigns a proprietary Growth Rating to each stock. The score is computed by evaluating various growth aspects, like EPS and revenue growth. We take into account the history as well as the estimated future numbers. NASDAQ:EXEL was assigned a score of 7 for growth:
ChartMill assigns a Valuation Rating to each stock, ranging from 0 to 10. This rating is calculated by analyzing different valuation elements, such as price to earnings and free cash flow, both in absolute terms and relative to the market and industry. In the case of NASDAQ:EXEL, the assigned 6 reflects its valuation:
ChartMill employs a unique Health Rating system for all stocks. This rating, ranging from 0 to 10, is determined by analyzing various liquidity and solvency ratios. For NASDAQ:EXEL, the assigned 7 for health provides valuable insights:
ChartMill utilizes a Profitability Rating to assess stocks, scoring them on a scale of 0 to 10. This rating takes into account a variety of profitability ratios and margins, both in absolute terms and in comparison to industry peers. NASDAQ:EXEL has earned a 7 out of 10:
More Affordable Growth stocks can be found in our Affordable Growth screener.
Our latest full fundamental report of EXEL contains the most current fundamental analsysis.
This article should in no way be interpreted as advice in any way. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.
43.09
-0.44 (-1.01%)
Find more stocks in the Stock Screener
EXELIXIS INC (NASDAQ:EXEL) shows strong growth momentum and meets Minervini’s trend criteria, making it a stock to watch for high-growth investors.
Wondering what's happening in Monday's pre-market session? Find an overview in this article.
EXELIXIS INC (NASDAQ:EXEL) meets key growth investing criteria with strong earnings, revenue growth, and profitability, making it a standout for investors following Louis Navellier's strategy.
EXELIXIS INC (NASDAQ:EXEL) offers strong growth, solid profitability, and reasonable valuation, making it a compelling choice for investors seeking affordable growth stocks in the biotech sector.
EXELIXIS INC (NASDAQ:EXEL) is an undervalued biotech stock with strong profitability, growth, and financial health, making it a compelling pick for value investors.
EXELIXIS INC (NASDAQ:EXEL) combines strong earnings momentum with a high technical rating, making it a standout for growth investors. The stock's breakout setup suggests potential upside.